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Abstract 
Epidermal 
ERBB family cell surface receptors, including epidermal growth factor receptor 
(EGFR) /ERBB1), are phosphorylated upon binding by various EGF family ligands 
and signal via multiple kinase pathways. EGFR signaling is enhanced due to 
mutational activation or overexpression of EGFR in more thanalmost half of 
glioblastomas. Still, pharmacological, the most common malignant primary brain 
tumor. Therapeutic targeting of EGFR in glioblastoma has remained largely 
unsuccessful in glioblastoma. . 
Here we explored EGFR pathway activation in a panel ofprofiled 9 long-term (LTC) 
and 5 glioma-initiating (GIC) cell lines. Since EGFR mRNA, EGFR protein and 
phosphorylated EGFR (pEGFR) did not correlate, we extended the analyses to 
determine mRNA and protein levels of the other EGFR family members, ERBB2,3, 
and 4, and mRNA  for expression of the EGF family ligands, EGF, transforming 
growth factor (TGF)-α, heparin-binding epidermal growth factor (HB-EGF), 
betacellulin (BTC), and epiregulin (EREG).and activation of ERBB family receptors 
and expression of their ligands. Receptors and ligands were abundantly expressed in 
the cell line panel, with patterns overall similar to glioblastomasglioblastoma 
expression profiles in vivo in the as deposited in The Cancer Genome Atlas (TCGA) 
database. No differences between LTC and GIC emerged. Irrespective of ligand or 
receptor expression, neither aan EGFR antibody, erbitux, nor an EGFR tyrosin 
kinase receptor inhibitor (TKI), gefitinib, nor an EGFR antibody, erbitux, were 
particularly active against LTC or GIC at clinically relevant concentrations. The 
selfSelf-renewal capacity of GIC was severely compromised by EGF withdrawal. This 
effect was , but rescued by TGF-α, but transforming growth factor alpha (TGF- α), 
although not by neuregulin-1 (NRG1).NRG-1). Subcellular fractionation indicated high 
levels of nuclear phosphorylated EGFR in all LTC and GIC. In LN-229 cells, pERBB2 
and pERBB3 were also detected in the nucleus. Nuclear pERBB2 was less sensitive, 
whereas pERBB3 was induced, in response to gefitinib. 
This study provides an extensive characterization of human glioma cell models, 
including stem-like models, with regard to ERBB receptor/ligand expression and 
signaling. Redundant signaling involving multiple ERBB family ligands and receptors 
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may contribute to the challenges of developing more efficaciouseffective EGFR-
targeted therapies for glioblastoma. 
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Introduction 
 
The ERBB protein family consists of 4 members:, ERBB1, ERBB2, ERBB3 and 
ERBB4. EGFR (ERBB1), which are activated upon ligand binding to the extracellular 
ligand binding domain, triggering receptor homo- or heterodimerization and 
phosphorylation of certain cytoplasmic tyrosine residues (Hynes & Lane 2005, 
Yarden & Sliwkowski 2001). Tyrosine autophosphorylation leads to the recruitment 
and activation of multiple targets and pathways, e.g., the mitogen-activated protein 
kinase (MAPK), the phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) and 
the Janus kinase/signal transducer and activator of transcription (JAK/STAT) 
pathways (Olayioye et al. 2000, Hynes et al. 2001, Yarden & Sliwkowski 2001).  
ERBB family proteins are activated by a group of related ligands: epidermal growth 
factor (EGF), transforming growth factor alpha (TGF-α) and amphiregulin (AR) bind 
specifically to epidermal growth factor receptor (EGFR/ERBB1), whereas heparin-
binding epidermal growth factor (HB-EGF), betacellulin (BTC) and epiregulin (EREG) 
bind to ERBB1 and ERBB4. The neuregulins (NRG1, 2, 3, 4) bind either to ERBB3 
and ERBB4 (NRG1,2) or to ERBB4 specifically (NRG3,4). Since none of the ligands 
can bind to ERBB2 alone and since ERBB3 has weak autophosphorylation 
properties, both receptors function mainly through heterodimerization with other 
ERBB receptors, preferentially with each other (Hynes et al. 2001, Yarden & 
Sliwkowski 2001, Graus-Porta et al. 1997, Steinkamp et al. 2014, Shi et al. 2010). 
EGFR is the most frequently amplified gene in glioblastoma (40%), resulting in 
increased ERBB1EGFR mRNA and protein levels, and exhibits mutation, 
rearrangement, deletions and altered splicing, leading to the expression of different 
aberrant transcript variants (Cancer Genome Atlas Research 2008, Brennan et al. 
2013). EGFR gene amplification is common in the classic or receptor tyrosine kinase 
(RTK) type 2 molecular subtype of isocitrate dehydrogenase (IDH)-wildtype 
glioblastoma (Sturm et al. 2012, Brennan et al. 2013). Half of EGFR-amplified 
glioblastomas carry a tumor-specific deletion variant (EGFRvIII) characterized by an 
in-frame deletion of exons 2-7, resulting in constitutive EGFR activation (Felsberg et 
al. 2017). Most studies of ERBB receptor family expression beyond EGFR in gliomas 
have used immunohistochemistry (IHC) techniques (Torp et al. 2007, Duhem-
Tonnelle et al. 2010, Weller et al. 2014, Felsberg et al. 2017) . In the absence of 
gene amplification, increased immunoreactivity for ERBB proteins in glioblastoma 
Field Code Changed
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may result from the receptor conformation status which depends on the activation 
level and modified dimerization profile rather than overexpression at the protein level 
alone (Duhem-Tonnelle et al. 2010).. ERBB1 and ERBB2 receptors exhibit highly 
variable expression profiles among glioblastoma samples, whereas ERBB3 and 
ERBB4 are expressed at lower levels than in control (non-neoplastic cerebral cortex) 
tissues. However, ERBB3 may be prominently expressed in CD133-positive putative 
tumor stem cells (Duhem-Tonnelle et al. 2010). Similarly, genes encoding the ERBB 
ligands EGF, transforming growth factor (TGF)--α, heparin-binding epidermal growth 
factor (HB-EGF), betacellulin (, BTC) and epiregulin (EREG) were reported to exhibit 
highly heterogeneous expression profiles among glioblastoma samples and derived 
cell lines. However, most neuregulin (NRG1, 2, 3, 4) genes arewere expressed at low 
levels relative to cerebral cortex (Duhem-Tonnelle et al. 2010). 
Exploiting EGFR as a therapeutic target in glioblastoma has remained challenging. 
Glioblastoma cell resistance to pharmacological EGFR inhibitors such as antibodies 
(cetuximab) or tyrosine kinase inhibitors (TKI) may be explained by compensatory 
activation of EGFR-related family members (ERBB2, ERBB3), enabling persistent 
glioblastoma cell proliferation, 
Exploiting EGFR as a therapeutic target in glioblastoma has remained challenging 
(Furnari et al. 2015). Glioblastoma cell resistance to pharmacological EGFR 
inhibitors including antibodies, such as cetuximab or tyrosine kinase inhibitors (TKI) 
such as gefitinib or erlotinib has been attributed to multiple reasons. The blood brain 
barrier may limit access to large molecules or hydrophilic molecules in tumor areas 
where the barrier is not disrupted (Lassman et al. 2005). Primary redundance of 
pathway activation, or compensatory pathway activation in response to interventions, 
may maintain down-stream signaling even when EGFR signaling is blocked (Hegi et 
al. 2011). This may involve EGFR-related family members such as ERBB2 or ERBB3 
since dual inhibition of EGFR and ERBB2 with lapatinib significantly reduced 
glioblastoma cell proliferation compared to cetuximab (Clark et al. 2012).. ERBB2 
itself has also attracted interest as a target structure for natural killer cell-based 
immunological treatment approaches in various cancers, including glioblastoma 
(Nowakowska et al. 2018, Ahmed et al. 2017). In contrast to the antibodies, 
cetuximab and trastuzumab, selective siRNA-mediated gene silencing of EGFR or 
ERBB2 in glioblastoma cells, reduced the growth rate in vitro by 40% and 65%, 
respectively. EGFR gene silencing did not change migration, however, silencing of 
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EGFR and ERBB2 reduced migration by 50% and induced radiosensitization in 
U251MG cells (Wichmann et al. 2015). T98G glioma cells incubated with antisense 
oligonucleotides to TGF-α exhibited growth inhibition in vitro (Rubenstein et al. 2001). 
Silencing of HB-EGF in U87MG cells, conditionally expressing either EGFRwt or 
EGFRvIII, attenuated EGFRvIII phosphorylation, inhibiting EGFRvIII-induced 
tumorigenicity, suggesting that an HB-EGF-EGFR/EGFRvIII loop regulates EGFRvIII 
activation (Li et al. 2014). Inhibition of NRG1 expression by siRNA reduced the 
mRNA levels of L1, a cell adhesion molecule, responsible for migration of 
glioblastoma cells in vitro (Zhao & Schachner 2013). Silencing of amphiregulin 
(AREG),, another ERBB ligand, reduced tumor growth by itself and rendered C6-4 
glioma cell-derived tumors sensitive to D9-tetrahydrocannabinol (THC) treatment 
(Lorente et al. 2009). Neutralizing antibodies to epiregulin (EREG) decreased cell 
proliferation in U87MG cells in vitro (Auf et al. 2013). Altogether, these studies 
indicate that ERBB signaling beyond EGFR may determine the biological behavior of 
glioblastoma cells, notably in the setting of pharmacological interference with EGFR 
signaling. 
Given the increasing interest in exploiting ERBB family receptors as targets for 
experimental therapy in brain tumors, which presently include vaccines (Weller et al. 
2017b), chimeric antigen receptor T cells (Sampson et al. 2014) and antibody drug 
conjugates (Gan et al. 2017), the present study was conducted to provide a 
comprehensive characterization of ERBB family ligand and receptor expression in a 
large set of human glioma models, including glioma-initiating cell (GIC) models. 
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Materials and Methods 
 
Reagents and cell lines 
Gefitinib (Iressa®) is an EGFR selective tyrosine kinase inhibitorTKI purchased from 
InvivoGen (tlrl-gef, San Diego, CA). Cetuximab (Erbitux®) was kindly provided by 
Merck (Darmstadt, Germany). Nine long-term glioblastoma cell lines (LTC) (LN-18 
(RRID:CVCL_0392), LN-428 (RRID:CVCL_3959), D247 (RRID:CVCL_1153), LN-319 
(RRID:CVCL_3958), A172 (RRID:CVCL_0131), U87MG (RRID:CVCL_0022), T98G 
(RRID:CVCL_0556), LN-308 (RRID:CVCL_0394), LN-229 (RRID:CVCL_0393)) 
(Weller et al. 1998) were maintained in Dulbecco´s modified Eagle´s medium 
(DMEM) supplemented with 10% fetal calf serum (FCS). Five glioma-initiating cell 
lines (GIC) (T-325, T-269, ZH-161 (RRID:CVCL_JZ64), S-24, ZH-305 
(RRID:CVCL_JZ65)) were isolated from surgically removed glioblastomas  (Lemke et 
al. 2014, Seystahl et al. 2015, Silginer et al. 2016) and cultured as spheres in 
neurobasal medium (NB) supplemented with 2% B27, 1% glutamine, EGF (20 
ng/ml), and basic fibroblast growth factor (bFGFFGF, 20 ng/ml).) (Table S1). They 
have never been exposed to FCS. LTC and GIC are routinely authenticated at the 
Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures in 
Braunschweig, Germany, last in 2016. LN-319 and U87MG are part of our panel of 
standard cell lines. They passed the test for verification, despite being listed as 
misidentified cell lines by the International Cell Line Authentication Committee 
(ICLAC). Recombinant human TGF-α and neuregulin 1β(100-16A) and neuregulinβ-1 
(heregulinβ-1) (100-03) were purchased from PeproTech (Rocky Hill, NJ). 
 
Real-time PCR (RT-PCR) 
Total mRNA extraction was performed using the NucleoSpin®RNA II system. 
(Macherey-Nagel AG, Oensingen SO, Switzerland). One 1 μg cDNA was prepared 
using the “High Capacity cDNA Reverse Transcription Kit” (Applied Biosystems by 
Thermo Fisher Scientific, Waltham, MA). Gene expression was measured by the 
QuantStudio™ 6 real-time PCR system and QuantStudio software V1.2 (Thermo 
Fisher Scientific) using PowerUpTM SYBR Green Master Mix (A25741) (Applied 
Biosystems by Thermo Fisher Scientific). Relative gene expression was calculated 
using a variation of the 2^(- delta delta CT) method (Livak & Schmittgen 2001). 
Hypoxanthine-guanine phosphoribosyltransferase 1 (HPRT1) expression was 
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selected for normalization. The following primers were used: HPRT1 (forward 5'-
TGAGGATTTGGAAAGGGTGT-3', reverse 5'-GAGCACACAGAGGGCTAC AA-3'); 
EGFR (forward 5’-GAGTCGGGCTCTGGAGGAAA-3’, reverse 5’-
CAGTTATTGAACATCCTCTGG AC-3’); ) (Felsberg et al. 2017, Weller et al. 
2014);ERBB2 (forward 5’-ATAGACACCAACCGCTCTCG-3’, reverse 5’-
ATCCTCAGAACTCTCTCCCCAG-3’); ERBB3 (forward 5’-
AACTCTCAGGCAGTGTGTCC-3’, reverse 5’-AGCACAATCTCAAGGTTCCCC-3’); 
ERBB4 (forward 5’-AGGATGTGGACGTTGCCATAAG-3’, reverse 5’-
ACCGTCCTTGTCAAAGTCTGG-3’); EGF (forward 5’-GTGTGCTGGACGCCTGTCT-
3’, reverse 5’-CTTACGGAATAGTGGTGGTCATCTT-3’): HB-EGF (forward 5’-
TGGGCATGACTAATTCCCACTG-3’, reverse 5’-AAGTCTTTCCCCTCTGCAGTC-3’); 
TGF-α (forward 5’-CCAGGTCCGAAAACACTGTGAG - 3’, reverse 5’- 
AAACTCCTCCTCTGGGCTCTTC-3’); EREG (forward 5’- 
ATCACAGTCGTCGGTTCCAC-3’, reverse 5’- CCATTCAGACTTGCGGCAAC-3’); 
BTC (forward 5’- GTGCAGCTACCACCACACAATC-3’, reverse 5’- 
TTCATCACAGACACAGGAGGGC-3’); NRG1 (forward 5’- 
TGTGTCTTCAGAGTCTCCCAT-3’, reverse 5’- AAGCACTCCCCTCCATTCAC-3’); 
NRG2 (forward 5’- GTGAGCACCACCCTGTCATC-3’, reverse 5’- 
TGGACATTTGCAGGAGAGCTG-5’); NRG3 (forward 5’- 
GCCCCAAATTTCATACGACGA-3’, reverse 5’- TATGGGATCCGGTCAGGGTT-3’); 
AREG (5’- TTGATACTCGGCTCAGGCCA-3’, reverse 5’- 
CCCCAGAAAATGGTTCACGC-3’). 
 
 
 
Immunoblot analysis 
Total protein extracts were prepared using radio-immunoprecipitation assay (RIPA) 
lysis buffer (pH 7.8) containing 25 mM Tris-HCl, 120 mM NaCl, 5 mM EDTA and 
0.5% NP-40 supplemented with 2 μg/mL aprotinin, 10 μg/mL leupeptin, 100 μg/mL 
phenylmethylsulfonyl fluoride, 200 mM sodium orthovanadate, 0.5 M NaF, protease 
inhibitor cocktail sets III and IV(P8340) and phosphatase inhibitor cocktails 2 (P5726) 
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and 3 (P0044) (Sigma Aldrich, St. Louis, MO). Nuclear and cytoplasmic sub-
fractionation of cultured cells was performed by NE-PER Nuclear and Cytoplasmic 
Extraction Reagents kit (78833, ThermoScientific, Waltham, MA). 
 Primary antibodies were as follows: rabbit anti-lamin B1 (1/2000, Ab 16048, 
RRID:AB_443298, Abcam, Cambridge, UK), rabbit anti-phospho-EGFR (Tyr 1068) 
(Cell Signaling Technology, CST, Danvers, Massachusetts), rabbit anti-EGFR (Sc-
03, Santa Cruz Biotechnology, Santa Cruz, CA),, rabbit anti-phospho-HER2/ERBB2 
(Tyr1221/1222), rabbit anti- HER2/ERBB2, rabbit anti-phospho-HER3/ERBB3 
(Tyr1289), rabbit anti-HER3/ERBB3 (all 1/1000, #8339, RRID:AB_10860426, Cell 
Signaling Technology, CST), and rabbit anti-LaminB1 (Ab 16048, 1/2000) (Abcam, 
Cambridge, UK)., Danvers, MA). The membranes were exposed to rabbit-anti goat 
IgG HRP antibody (1/5000, sc-2768, RRID:AB_656964, Santa Cruz Biotechnology) 
or to HRP-conjugated secondary rabbit antibody (Santa Cruz Biotechnology1/5000, 
#7074, RRID:AB_2099233, CST). Protein levels were quantified by NIH ImageJ 
densitometric software (http://rsb.info.nih.gov/ij/). Band intensity was normalized to 
actin or GAPDH loading control.(1/1000, sc-1616, RRID:AB_630836, Santa Cruz 
Biotechnology) or GAPDH (1/1000, EB07069, RRID:AB_2247304, Everest Biotech 
Ltd, Bicester, UK) loading controls.  
 
Proliferation, clonogenicity and spherogenicity assays 
Proliferation assays were performed in a 96-well format, seeding 5’000- 30’000 cells / 
well. cells / well for LN-18, LN-428, LN-319, A172, U87MG, T98G and LN-229, 
10’000-15’000 cells / well for D247MG, LN-308, T-325 and ZH-161, and 30’000 cells 
/ well for T-269, S-24 and ZH-305. To assess colony formation of LTC or 
spherogenicity of GIC, cells were seeded at different densities (50-100 cells for LTC 
and 300 cells for GIC) in 96-well plates. LTC were allowed to attach in complete 
DMEM for 24 h. Then the medium was replaced by DMEM in the absence or 
presence of the corresponding agent. GIC were allowed to form spheres for 24 h in 
complete NB medium and then supplemented with drugs at the final concentrations, 
as indicated. After 72 h (proliferation assay), or 8-16 days (clonogenicity), or 20 days 
(spherogenicity), metabolic activity was assessed by MTT (3-(4, 5-dimethylthiazolyl-
2)-2, 5-diphenyltetrazolium bromide) reduction. 
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Statistical analysis 
Data reported here were derived from biological and technical replicates. 
Representative data of experiments, performed two to three times using triplicate 
wells for viability and proliferation assays and duplicate wells for RT-PCR, are shown. 
Quantitative data were expressed as the mean ± standard error of mean (SEM). The 
statistical analyses were performed by the one-way ANOVA or two-way ANOVA with 
Bonferroni’s multiple comparison tests (GraphPad Software, La Jolla, CA). Pearson’s 
correlation coefficient was used in order to calculate correlations between mRNA and 
protein data. A p-value of p<0.05 was considered statistically significant. This study 
was not pre-registered, does not need institutional approval, and no randomization or 
blinding was used. 
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Results 
 
Expression and activity of EGFR family members in human glioma cells 
We first determined EGFR mRNA expression in the cell line panel. It varied strongly 
among cell lines with a fold difference of 44.6 between D247MG and LN-319 among 
the LTC or, and of 11.5 between T-269 and T-325 among the GIC. Expression 
models. There was no difference in expression levels did not generally differ between 
pooled LTC and pooled GIC (Fig. 1A). Expression of the deletion variant, EGFRvIII 
mRNA, was not expresseddetected in any cell line, usingbut EGFRvIII mRNA was 
readily detected in EGFRvIII-transfected LN-229 cells (Fan et al. 2013) which were 
used as a positive control (data not shown). EGFR protein was detected in all cell 
lines. pEGFRTyr1068, phosphorylated EGFR (pEGFR) was also detected as 3 
immunoreactive bands between 100 and 260 kDa in many, but not all cell lines (Fig. 
1B). The signal specificity was confirmed by demonstrating that the immunoreactive 
bands decreased in response to increasing concentrations of gefitinib (Fig. 1D). The 
majority of pEGFR was localized in the nuclear compartment (Fig., albeit at very low 
levels in LN-319.1C). Quantification of protein bands using densitometry indicated 
that relative to total EGFR protein levels, pEGFR levels in GIC were higher in GIC 
than in LTC, with a pEGFR/EGFR ratio of 1.62 in GIC versus 0.448 in LTC (Fig. 1B) 
which may be). This is likely due to EGF supplementation in the GIC culture medium. 
The signal specificity for EGFR was confirmed by a decrease in response to the 
EGFR TKI gefitinib (Fig. 1C).Overall, there was no  There was overall no correlation 
between EGFR mRNA and EGFR protein and only a trend for negative correlation 
between, total EGFR protein and pEGFR (Table S1).S2), suggesting the existence of 
regulatory pathways of EGFR phosphorylation beyond EGFR gene expression. 
To better understand the differences among pEGFR levels in the cell line panel, 
Expression of ERBB receptor family members in human glioma cells 
Next we determined the expression of ERBB family members (Fig. 2A-E) and their 
ligands (Fig. 3).in the glioma cell line panel. ERBB2 mRNA was expressed in all cell 
lines except ZH-161 (Fig. 2A). The. By far the highest ERBB3 mRNA level was found 
in LN-229 whereas LN-428, D247MG, LN-308, S-24 and ZH-305 had low levels, and 
T98G was negative (Fig. 2B).. ERBB4 mRNA was not detectable in the half of the 
cell line panel and varied considerably between verydetected at low andto moderate 
expression levels among the other cell lines (Fig. 2C). mRNA and protein levels 
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correlated for ERBB2 and ERBB3 (Fig. 2A,B,D,E, Table S1),. ERBB2 protein varied 
considerably among cell lines whereas ERBB3 protein was detected at high levels in 
LN-229 cells only (Fig. 2). ERBB4 protein was not detected in any of glioma cell lines 
(data not shown). mRNA and protein levels correlated for ERBB2 and ERBB3 (Table 
S2). Compared with the cell line panel, TCGA analysis disclosed a similar relative 
abundance of ERBB mRNA species in human glioblastomas in vivo. It indicated and 
revealed trend for correlation between high expression levels and inferior survival for 
EGFR and ERBB2, but not ERBB3 or ERBB4 (Fig. S1).  
Expression of ERBB ligands in human glioma cells 
Next we determined the expression of ERBB family ligands in the glioma cell line 
panel. S-24 was the only EGF mRNA-negative cell line. At mRNA levels, EREG (in 
some cell lines), TGF-α and NRG1 were the dominant ligands. T98G was the only 
TGF-α-negative cell line. High EREG mRNA expression was detected in LN-18, 
U87MG and T-325 cells. BTC showed low or no expression in most of the cell lines. 
GIC had lower NRG1 mRNA expression than LTC, LN-308 was the only one LTC 
with low NRG1 mRNA. Low NRG2 mRNA expression was detected only in LN-319 
and LN-308, the other cell lines showed higher mRNA levels. ZH-305 was the only 
NRG3 mRNA -positive cell line. ZH-161 and ZH-305 were the only AREG -positive 
cell lines, yet with very low expression (Fig. 3). EGFR ligandThere were correlations 
between EREG and BTC as well as between EGF and NRG1 gene expression 
appeared to be co-regulated within the GIC panel, but not(Table S3). Expression of 
NRG1, an exclusive ERBB3 and ERBB4 ligand, correlated with ERBB1 mRNA, 
pEGFR in LTC (Table S2). Notablyand with ERBB2 mRNA. Similarly, TGF-α, an 
EGFR specific ligand, correlated strongly with ERBB2 protein level as well as with 
ERBB3 mRNA expression correlated with the levels of EGFR and ERBB2 protein 
(Table S3S4). TCGA analysis showed similar relative expression levels of ERBB 
ligands, e.g., low level expression of AREG and NRG2-4, and revealed no major 
correlation between expression levels and survival (Fig. S2). 
 
Biological activity of EGFR signaling in maintaining the GIC phenotype 
Next, we analyzed glioma cell sensitivity to different anti-EGFR agents, gefitinib, a 
TKI of EGFR, and erbitux, ana neutralizing antibody to EGFR. Neither LTC nor GIC 
were particularly sensitive to these agents in 72 h continuous exposure assays 
(Table 1, Fig. S3). In order to investigate the role of ERBB ligand family members for 
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sphere formation, limiting dilution assays were performed in four GIC lines. Omission 
of EGF from the medium expectedly abrogated sphere formation in all GIC. 
Accordingly, gefitinib decreased spherogenicity (Fig. 4)., too. Replacement of EGF by 
TGF-α maintained sphere formation (Fig. 4). In contrast, neuregulin -1 had no such 
effect (data not shown). Accordingly, exposure to exogenous EGF or TGF-α induced 
pEGFR levels strongly, whereas withdrawal of EGF or exposure to gefitinib 
abrogated EGFR phosphorylation (Fig. 4E), corroborating the spherogenicity data. 
 
 
 
Nuclear localization and subcellular regulation of ERBB receptors 
It has been previously shown that EGFR can translocate from the membrane to the 
nucleus and may contribute to drug resistance (Brand et al. 2011, Li et al. 2009, Fan 
et al. 2013). Therefore, we performed subcellular fractionation for all LTC and GIC in 
order to assess nuclear versus cytoplasmic fractions of phosphorylated and total 
EGFR. Unexpectedly, the majority of pEGFR was localized in the nuclear 
compartment (Fig. 5A). Both nuclear and cytoplasmic EGFR were simultaneously 
decreased when ZH-161 and S-24 cells were exposed to gefitinib. Moreover, gefitinib 
treatment prior to EGF stimulation prevented nuclear and cytoplasmic pEGFR 
induction by subsequent stimulation (Fig. 5B). Interestingly, nuclear localization was 
also observed for ERBB2 and ERBB3 in LN-229 cells. pERBB2, and less so 
pERBB3, increased in response to EGF, but only in the cytoplasmic compartment. 
pERBB2 was decreased by gefitinib in both fractions, although less so in the nuclear 
compartment, whereas cytoplasmic pERBB3 strongly increased in response to 
gefitinib (Fig. 5C). 
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Discussion 
 
The EGFR gene is the most commonly amplified and overexpressed proto-oncogene 
and a frequent mutational target in glioblastoma. EGFR gene amplification is 
detectable in approximately 40% of all glioblastomas and common in the classic or 
receptor tyrosine kinase (RTK) type 2 molecular subtype of isocitrate 
dehydrogenase-wildtype glioblastoma The present comprehensive characterization 
of expression and biological activity of ERBB family receptors and their ligands in a 
large panel of glioma models was conducted because of the increasing interest in 
targeting these molecules for the treatment of glioblastoma. Such treatment 
approaches directed mainly to EGFR (ERBB1), but also to HER2 (ERBB2) include 
tyrosine kinase inhibitors, unarmed antibodies, antibody drug conjugates, vaccines 
and even cellular immunotherapies (SturmWeller et al. 2012, Brennan2017b, 
Sampson et al. 20132014). Half of EGFR-amplified glioblastomas carry a tumor-
specific deletion variant (EGFRvIII) that is , highlighting the urgent need to better 
understand this receptor ligand system in glioblastoma. 
characterized by an in-frame deletion of exons 2-7, resulting in constitutive EGFR 
activation (Felsberg et al. 2017). The failure of EGFR TKI to improve outcome has 
been attributed to insufficient target coverage, e.g., because of limited blood brain 
barrier penetration or the redundance of TK-dependent signalling pathways in 
glioblastoma or both (Furnari et al. 2015). 
Here, we explored expression and biological activity of EGF/EGFR-related ligands 
and receptors which are known to exhibit potential for cross-talk with the EGFR 
sigaling pathway in a panel of human glioma cell lines, including GIC models. We 
find that the EGFR pathway shows heterogeneous patternsis activated as confirmed 
by the detection of activationpEGFR in almost all glioma cell linesmodels in vitro (Fig. 
1). The interpretation of cell culture data on the biological role of the EGFR pathway 
is limited by the factThis was surprising since it has previously been observed that 
EFGREGFR amplification including and in particular expression of the EGFRvIII 
expression isdeletion mutation are commonly lost upon prolonged glioma cell 
maintenance in culture (Pandita et al. 2004, Bigner et al. 1990).  
Field Code Changed
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EGF and related ligands are present in the FCS which is used to maintain the LTC in 
culture (Pandita et al. 2004, Bigner et al. 1990), and thatover years, but pEGFR was 
maintained in most models even under the experimental conditions of serum-free 
culture used in Fig. 1. In contrast, supplementing EGF is essential in most 
contemporary paradigms of maintaining GIC cultures, as confirmed here in Fig. 4.  
(Lathia et al. 2015) and likely accounts for the relatively higher pEGFR levels in GIC 
models than in LTC models (Fig. 1). 
Beyond EGFR, cultured glioma cells also express other ERBB family members, 
notably ERBB2 and ERBB3, and exhibit ERBB phosphorylation, suggesting pathway 
activity, but in a highly cell line-specific manner (Fig. 2).2). The relative expression 
levels allow to speculate that GIC preferentially signal via EGFR dimers or 
EGFR/ERBB2 heterodimers whereas the widely used LN-229 model may also signal 
via ERBB2/ERBB3 heterodimers since both were expressed relatively high relative to 
EGFR. Importantly, expression patterns in the cell line panel resembled expression 
data deposited in the TCGA database (Fig. S1). ), suggesting that such cell culture 
models may be appropriate tools to explore ERBB family molecule-directed 
therapies. 
There was also widespread expression of EGF family ligands in the glioma cell line 
panel (Fig. 3), and some) that resembled patterns of expression in the TCGA 
database (Fig. S2). Some of these genes appeared to be transcriptionally co-
regulated (Tables S2, S3). Finally, thereS3, S4), indicating up-stream common 
regulatory pathways that might be better amenable to therapeutic intervention. 
There is to date only limited data on the biological role of EGF-related growth factors 
in maintaining the malignant phenotype of gliomas. EGF and FGF are typically 
included in the cell culture medium used to generate patient-derived glioma cell lines 
directly ex vivo. In that regard, we observed that at least TGF-α, which acts on 
EGFR, but not NRG1, which only acts on ERBB3 and ERBB4, may well compensate 
for EGF in situations at the levelterms of EGFR phosphorylation and sphere 
formation where EGF supply is suppressed (Fig. 4).4). The almost universal 
resistance of glioma models in vitro to clinically relevant concentrations of gefitinib or 
erbitux (Table 1) precluded an analysis of patterns of receptor and ligand expression 
associated with sensitivity or resistance to EGFR targeting. 
Once activated by phosphorylation, EGFR not only induces down-stream signaling, 
but also enters the cytosol. Several lines of evidence indicates that a significant 
 16 
 
amount of EGFR enters the nucleus of glioma cells to exert specific functions (Burel-
Vandenbos et al. 2013, Fan et al. 2013), e.g., promoting transcription of the 
antiapoptotic BCL-XL gene (Latha et al. 2013) or modulating DNA repair (Dittmann et 
al. 2005). It is also believed that nuclear EGFR can retain its tyrosine kinase activity 
and phosphorylate further substrates (Wang et al. 2006). Our analyses confirm the 
accumulation of pEGFR in the nucleus (Fig. 5). We observed that either EGF 
stimulation or gefitinib treatment increased or decreased cytoplasmic as well as 
nuclear pEGFR simultaneously (Fig. 5B, C), suggested activity at both sites or rapid 
cycling. Importantly, besides EGFR, ERBB2 and ERBB3 may also exhibit nuclear 
localization. Both may contribute to evasive resistance to EGFR targeting by TKI 
since pERBB2 in the nucleus was poorly responsive to gefitinib and since pERBB3 
even paradoxically increased in both compartments (Fig. 5C). Nuclear localization of 
ERBB3 was previously reported in breast cancer cells (Offterdinger et al. 2002), but 
these authors observed a lack of nuclear ERBB2 and absent nuclear phosphorylation 
of ERBB3. Sustained phosphorylation of ERBB3 can be explained by the presence of 
nuclear ERBB2 once pEGFR is decreased upon gefitinib treatment. 
Overexpression of ERBB ligands has been linked to nuclear translocation of EGFR in 
non-small cell lung cancer cells (Li et al. 2009) and its  
 
nuclear accumulation has been suggested to be in part responsible for intrinsic 
resistance to inhibitors targeting EGFR at the cell surface. Sustained nuclear 
pERBB2 and increased cytoplasmic phosphorylation levels of ERBB3 as observed in 
LN-229 cells (Fig. 5) warrants efforts to develop therapies targeting multiple ERBB 
molecules.  
Despite disappointing results with EGFR TKI or EGFRvIII-directed vaccines (Weller 
et al. 20172017a, Furnari et al. 2015), targeting EGFR as one of the dominant 
molecular lesions in glioblastoma will continue to be studied, with antibody drug 
conjugates such as ABT-414 being the most promising approach at present (van den 
Bent et al. 2017)(van den Bent et al. 2017, Gan et al. 2017). A better understanding 
of the role of other ERBB family ligands and receptors in modulating constitutive or 
acquired resistance to EGFR targeting in glioblastoma should help to guide 
therapeutic strategies and to potentially enrich for patient populations most likely to 
derive benefit. The present dataset will facilitate the choice of appropriate cell culture 
models for future studies on ERBB family protein-directed therapies in glioblastomas. 
 17 
 
 
 
 
 
 
 18 
 
Competing interest 
 
This work was supported by an unrestricted research grant from Abbvie to M.W.. 
M.W. has received further research grants from Acceleron, Actelion, Bayer, Merck, 
Sharp & Dohme (MSD), Merck (EMD), Novocure, OGD2, Piqur, Roche and Tragara, 
and honoraria for lectures or advisory board participation or consulting from Abbvie, 
BMS, Celgene, Celldex, Merck, Sharp & Dohme (MSD), Merck (EMD), Novocure, 
Orbus, Pfizer, Progenics, Roche, Teva and Tocagen, all unrelated to this work. C.v.A. 
and E.S. declare that they have no conflict of interests. 
 
 
 
 19 
 
References 
Ahmed, N., Brawley, V., Hegde, M. et al. (2017) HER2-Specific Chimeric Antigen Receptor-Modified 
Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA 
Oncol, 3, 1094-1101. 
Auf, G., Jabouille, A., Delugin, M. et al. (2013) High epiregulin expression in human U87 glioma cells 
relies on IRE1alpha and promotes autocrine growth through EGF receptor. BMC Cancer, 13, 
597. 
Bigner, S. H., Humphrey, P. A., Wong, A. J., Vogelstein, B., Mark, J., Friedman, H. S. and Bigner, D. D. 
(1990) Characterization of the epidermal growth factor receptor in human glioma cell lines 
and xenografts. Cancer Res, 50, 8017-8022. 
Brand, T. M., Iida, M., Li, C. and Wheeler, D. L. (2011) The nuclear epidermal growth factor receptor 
signaling network and its role in cancer. Discov Med, 12, 419-432. 
Brennan, C. W., Verhaak, R. G., McKenna, A. et al. (2013) The somatic genomic landscape of 
glioblastoma. Cell, 155, 462-477. 
Burel-Vandenbos, F., Turchi, L., Benchetrit, M. et al. (2013) Cells with intense EGFR staining and a 
high nuclear to cytoplasmic ratio are specific for infiltrative glioma: a useful marker in 
neuropathological practice. Neuro-Oncology, 15, 1278-1288. 
Cancer Genome Atlas Research, N. (2008) Comprehensive genomic characterization defines human 
glioblastoma genes and core pathways. Nature, 455, 1061-1068. 
Clark, P. A., Iida, M., Treisman, D. M., Kalluri, H., Ezhilan, S., Zorniak, M., Wheeler, D. L. and Kuo, J. S. 
(2012) Activation of multiple ERBB family receptors mediates glioblastoma cancer stem-like 
cell resistance to EGFR-targeted inhibition. Neoplasia, 14, 420-428. 
Dittmann, K., Mayer, C., Fehrenbacher, B., Schaller, M., Raju, U., Milas, L., Chen, D. J., Kehlbach, R. 
and Rodemann, H. P. (2005) Radiation-induced epidermal growth factor receptor nuclear 
import is linked to activation of DNA-dependent protein kinase. J Biol Chem, 280, 31182-
31189. 
Duhem-Tonnelle, V., Bieche, I., Vacher, S. et al. (2010) Differential distribution of erbB receptors in 
human glioblastoma multiforme: expression of erbB3 in CD133-positive putative cancer stem 
cells. J Neuropathol Exp Neurol, 69, 606-622. 
Fan, Q. W., Cheng, C. K., Gustafson, W. C. et al. (2013) EGFR phosphorylates tumor-derived EGFRvIII 
driving STAT3/5 and progression in glioblastoma. Cancer Cell, 24, 438-449. 
Felsberg, J., Hentschel, B., Kaulich, K. et al. (2017) Epidermal Growth Factor Receptor Variant III 
(EGFRvIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison 
between Primary and Recurrent Tumors. Clin Cancer Res, 23, 6846-6855. 
Furnari, F. B., Cloughesy, T. F., Cavenee, W. K. and Mischel, P. S. (2015) Heterogeneity of epidermal 
growth factor receptor signalling networks in glioblastoma. Nat Rev Cancer, 15, 302-310. 
Gan, H. K., Reardon, D. A., Lassman, A. B. et al. (2017) Safety, Pharmacokinetics and Antitumor 
Response of Depatuxizumab Mafodotin as Monotherapy or in Combination with 
Temozolomide in Patients with Glioblastoma. Neuro Oncol. 
Graus-Porta, D., Beerli, R. R., Daly, J. M. and Hynes, N. E. (1997) ErbB-2, the preferred 
heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J, 
16, 1647-1655. 
Hegi, M. E., Diserens, A. C., Bady, P. et al. (2011) Pathway analysis of glioblastoma tissue after 
preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial. Mol 
Cancer Ther, 10, 1102-1112. 
Hynes, N. E., Horsch, K., Olayioye, M. A. and Badache, A. (2001) The ErbB receptor tyrosine family as 
signal integrators. Endocr Relat Cancer, 8, 151-159. 
Hynes, N. E. and Lane, H. A. (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. 
Nat Rev Cancer, 5, 341-354. 
Lassman, A. B., Rossi, M. R., Raizer, J. J. et al. (2005) Molecular study of malignant gliomas treated 
with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain 
Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res, 11, 7841-7850. 
Formatted: Left, Indent: Left:  0 cm, Hanging:  1.27 cm, Line
spacing:  single
 20 
 
Latha, K., Li, M., Chumbalkar, V. et al. (2013) Nuclear EGFRvIII-STAT5b complex contributes to 
glioblastoma cell survival by direct activation of the Bcl-XL promoter. International journal of 
cancer. Journal international du cancer, 132, 509-520. 
Lathia, J. D., Mack, S. C., Mulkearns-Hubert, E. E., Valentim, C. L. L. and Rich, J. N. (2015) Cancer stem 
cells in glioblastoma. Genes & Development, 29, 1203-1217. 
Lemke, D., Weiler, M., Blaes, J. et al. (2014) Primary glioblastoma cultures: can profiling of stem cell 
markers predict radiotherapy sensitivity? J Neurochem, 131, 251-264. 
Li, C., Iida, M., Dunn, E. F., Ghia, A. J. and Wheeler, D. L. (2009) Nuclear EGFR contributes to acquired 
resistance to cetuximab. Oncogene, 28, 3801-3813. 
Li, L., Chakraborty, S., Yang, C. R. et al. (2014) An EGFR wild type-EGFRvIII-HB-EGF feed-forward loop 
regulates the activation of EGFRvIII. Oncogene, 33, 4253-4264. 
Livak, K. J. and Schmittgen, T. D. (2001) Analysis of relative gene expression data using real-time 
quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-408. 
Lorente, M., Carracedo, A., Torres, S. et al. (2009) Amphiregulin is a factor for resistance of glioma 
cells to cannabinoid-induced apoptosis. Glia, 57, 1374-1385. 
Nowakowska, P., Romanski, A., Miller, N., Odendahl, M., Bonig, H., Zhang, C., Seifried, E., Wels, W. S. 
and Tonn, T. (2018) Clinical grade manufacturing of genetically modified, CAR-expressing NK-
92 cells for the treatment of ErbB2-positive malignancies. Cancer Immunol Immunother, 67, 
25-38. 
Offterdinger, M., Schöfer, C., Weipoltshammer, K. and Grunt, T. W. (2002) c-erbB-3: a nuclear protein 
in mammary epithelial cells. The Journal of Cell Biology, 157, 929-940. 
Olayioye, M. A., Neve, R. M., Lane, H. A. and Hynes, N. E. (2000) The ErbB signaling network: receptor 
heterodimerization in development and cancer. EMBO J, 19, 3159-3167. 
Pandita, A., Aldape, K. D., Zadeh, G., Guha, A. and James, C. D. (2004) Contrasting in vivo and in vitro 
fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer, 
39, 29-36. 
Rubenstein, M., Glick, R., Lichtor, T., Mirochnik, Y., Chou, P. and Guinan, P. (2001) Treatment of the 
T98G glioblastoma cell line with antisense oligonucleotides directed toward mRNA encoding 
transforming growth factor-alpha and the epidermal growth factor receptor. Med Oncol, 18, 
121-130. 
Sampson, J. H., Choi, B. D., Sanchez-Perez, L. et al. (2014) EGFRvIII mCAR-modified T-cell therapy 
cures mice with established intracerebral glioma and generates host immunity against 
tumor-antigen loss. Clinical cancer research : an official journal of the American Association 
for Cancer Research, 20, 972-984. 
Seystahl, K., Tritschler, I., Szabo, E., Tabatabai, G. and Weller, M. (2015) Differential regulation of 
TGF-beta-induced, ALK-5-mediated VEGF release by SMAD2/3 versus SMAD1/5/8 signaling in 
glioblastoma. Neuro Oncol, 17, 254-265. 
Shi, F., Telesco, S. E., Liu, Y., Radhakrishnan, R. and Lemmon, M. A. (2010) ErbB3/HER3 intracellular 
domain is competent to bind ATP and catalyze autophosphorylation. Proceedings of the 
National Academy of Sciences of the United States of America, 107, 7692-7697. 
Silginer, M., Burghardt, I., Gramatzki, D. et al. (2016) The aryl hydrocarbon receptor links integrin 
signaling to the TGF-beta pathway. Oncogene, 35, 3260-3271. 
Steinkamp, M. P., Low-Nam, S. T., Yang, S., Lidke, K. A., Lidke, D. S. and Wilson, B. S. (2014) erbB3 is 
an active tyrosine kinase capable of homo- and heterointeractions. Mol Cell Biol, 34, 965-
977. 
Sturm, D., Witt, H., Hovestadt, V. et al. (2012) Hotspot mutations in H3F3A and IDH1 define distinct 
epigenetic and biological subgroups of glioblastoma. Cancer Cell, 22, 425-437. 
Torp, S. H., Gulati, S., Johannessen, E. and Dalen, A. (2007) Coexpression of c-erbB 1-4 receptor 
proteins in human glioblastomas. An immunohistochemical study. J Exp Clin Cancer Res, 26, 
353-359. 
van den Bent, M., Eoli, M., Sepulveda, J. M. et al. (2017) Ltbk-04 First Results of the Randomized 
Phase Ii Study on Depatux –M Alone, Depatux-M in Combination with Temozolomide and 
 21 
 
Either Temozolomide or Lomustine in Recurrent Egfr Amplified Glioblastoma: First Report 
from Intellance 2/Eortc Trial 1410. Neuro-Oncology, 19, vi316-vi316. 
Wang, S. C., Nakajima, Y., Yu, Y. L. et al. (2006) Tyrosine phosphorylation controls PCNA function 
through protein stability. Nat Cell Biol, 8, 1359-1368. 
Weller, M., Butowski, N., Tran, D. D. et al. (2017a) Rindopepimut with temozolomide for patients 
with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-
blind, international phase 3 trial. Lancet Oncol, 18, 1373-1385. 
Weller, M., Kaulich, K., Hentschel, B. et al. (2014) Assessment and prognostic significance of the 
epidermal growth factor receptor vIII mutation in glioblastoma patients treated with 
concurrent and adjuvant temozolomide radiochemotherapy. Int J Cancer, 134, 2437-2447. 
Weller, M., Rieger, J., Grimmel, C., Van Meir, E. G., De Tribolet, N., Krajewski, S., Reed, J. C., von 
Deimling, A. and Dichgans, J. (1998) Predicting chemoresistance in human malignant glioma 
cells: the role of molecular genetic analyses. Int J Cancer, 79, 640-644. 
Weller, M., Roth, P., Preusser, M., Wick, W., Reardon, D. A., Platten, M. and Sampson, J. H. (2017b) 
Vaccine-based immunotherapeutic approaches to gliomas and beyond. Nat Rev Neurol, 13, 
363-374. 
Wichmann, H., Guttler, A., Bache, M., Taubert, H., Rot, S., Kessler, J., Eckert, A. W., Kappler, M. and 
Vordermark, D. (2015) Targeting of EGFR and HER2 with therapeutic antibodies and siRNA: a 
comparative study in glioblastoma cells. Strahlenther Onkol, 191, 180-191. 
Yarden, Y. and Sliwkowski, M. X. (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol, 
2, 127-137. 
Zhao, W. J. and Schachner, M. (2013) Neuregulin 1 enhances cell adhesion molecule l1 expression in 
human glioma cells and promotes their migration as a function of malignancy. J Neuropathol 
Exp Neurol, 72, 244-255. 
 Formatted: Line spacing:  1.5 lines
 22 
 
Table 1. Growth inhibitory effects of gefitinib and erbitux in glioma cells in 
vitro.* 
                        EC50 (µM) 
             Metabolic activity (72 h) 
 
Cell 
lines 
Gefitinib Erbitux 
LN-18 > 10 µM > 100 µg/ml 
LN-428 > 10 µM > 100 µg/ml 
D247MG > 10 µM Nd 
LN-319 > 10 µM > 100 µg/ml 
A172 > 10 µM > 100 µg/ml 
U87MG > 10 µM > 100 µg/ml 
T98G > 10 µM > 100 µg/ml 
LN-308 > 10 µM > 100 µg/ml 
LN-229  6 µM > 100 µg/ml 
T-325 > 10 µM > 100 µg/ml 
T-269    10 µM > 100 µg/ml 
ZH-161 > 10 µM > 100 µg/ml 
S-24    0.3 µM > 100 µg/ml 
ZH-305 > 10 µM Nd 
 
*EC50 values for growth inhibition were determined by MTT assay at 72 h exposure. 
(n=4 technical replicates). 
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Figure legends 
 
Figure 1. Characterization of LTC and GICthe long-term glioblastoma cell line 
panel(LTC) and glioma-initiating cell line (GIC) panels for EGFR expression and 
activity.phosphorylation. A,B. The cells were assessed for mRNA expression of 
epidermal growth factor receptor (EGFR (/ERBB1) (Arepresentative results of at least 
2 biological replicates are depicted with n=2 technical replicates) by RT-PCR, (A), as 
well as for total and phosphorylated and total EGFR protein levels in total cell lysates 
by immunoblot (representative results of 2 biological replicates) (B). C. Cells were 
also evaluated for the subcellular localization of phosphorylated and total EGFR 
protein levels in different cellular compartments by using nuclear (N) and 
cytoplasmic/membrane (C) fractionation. D. LN-229, T-269 or S-24 cells were 
exposed to 0.1, 1 or 10 µM gefitinib for 24 h and pEGFR levels were assessed by 
immunoblot. (representative results of n=2 biological replicates). Actin (B,C) or 
GAPDH (D) servedC) were used as loading controls, lamin B1 was used as 
membrane fraction loading control (C).. 
 
Figure 2. ERBB receptor family expression and activity. A-E. The cells were 
assessed for ERBB2, ERBB3 and ERBB4 gene expression (A-Crepresentative 
results of at least 2 biological replicates are depicted with n=2 technical replicates) by 
RT-PCR, (A-C), as well as for total and phosphorylated and total protein levels by 
immunoblot (n=1) (D,E). Actin served as a loading control. (D,E). 
 
Figure 3. ERBB ligand expression. Quantification of the ERBB ligand mRNA 
expression by RT-PCR: epidermal growth factor (EGF, ), heparin-binding epidermal 
growth factor (HB-EGF, ), transforming growth factor alpha (TGF-α, ), epiregulin 
(EREG, ), betacellulin (BTC, ), neuregulin (NRG1-3) and amphiregulin (AREG.) 
(representative results of at least 2 biological replicates are depicted with n=2 
technical replicates). 
 
Figure 4. ERBB ligand rescue upon epidermal growth factor (EGF) withdrawal-
mediated loss of glioma-initiating cell lines (GIC) sphere formation. T-325 (A), 
ZH-161 (B), S-24 (C) or ZH-305 (D) cells were seeded at densities of 30, 100 or 300 
cells per well in 96 well plates in medium containing EGF (20 ng/ml) plus fibroblast 
 24 
 
growth factor (FGF) (20 ng/ml), FGF (20 ng/ml) only, transforming growth factor 
alpha (TGF-α) (60 ng/ml) plus FGF (20 ng/ml), or EGF (20 ng/ml) plus FGF (20 
ng/ml) plus gefitinib (10 μM). Metabolic activity was assessed by MTT assay after 20 
days. Data are expressed as mean ± SEM (**p<0.01, ***p<0.001: + EGF/+FGF vs -
EGF/+FGF, #p<0.05, # # #p<0.001: - EGF/+FGF vs -EGF/+FGF/+TGF-α, ɸɸp<0.01, 
ɸɸɸp<0.001: +EGF/+FGF vs +EGF/+FGF/+gefitinib). E. pEGFR, two-way ANOVA with 
Bonferroni correction) (representative results of 2 biological replicates are depicted 
with n=2 technical replicates). E. Phosphorylated epidermal growth factor receptor 
(pEGFR) levels were determined at 24 h without or with EGF (50 ng/ml, 15 min) or 
TGF-α (150 ng/ml, 15 min) exposure, as well as with gefitinib (10 μM) treatment, by 
immunoblot. (n=1). GAPDH served as loading control. 
 
Figure 5. Cytoplasmic and nuclear localization of ERBB receptors. Cells were 
also evaluated for the subcellular localization of phosphorylated and total EGFR 
protein levels by using nuclear (N) and cytoplasmic (C) fractionation (A). B. ZH-161 
or S-24 were either deprived of EGF for 24 h, or pretreated with 10 μM gefitinib for 24 
h, and were then stimulated with EGF (50 ng/ml) for 15 or 60 min. C. LN-229 cells 
were pretreated with gefitinib and stimulated with EGF as described in B and 
assessed for pERBB1/ERBB1, pERBB2/ERBB2 and pERBB3/ERBB3 (n=1). GAPDH 
served as loading control, lamin B1 was used as nuclear fraction loading control. 
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Epidermal growth factor receptor and ligand family 
expression and activity in glioblastoma 
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 Supplementary Figure 1. Association of gene expression levels of ERBB family 
receptors with survival in glioblastoma patients. Kaplan Meier survival curves 
comparing gene expression status (high or low) are shown within the glioblastoma data 
set of the Cancer Genome Atlas network (TCGA) database using 'R2: Genomics 
Analysis and Visualization Platform (http://r2.amc.nl)' based on median (left panels) or 
optimum with limitations of quartile normalization (right panels) cut-off modus. 
Statistical significances (log-rank test) are indicated. 
 
 
Supplementary Figure 2. Association of gene expression levels of EGF family 
ligands with survival in glioblastoma patients. Kaplan Meier survival curves 
comparing gene expression status (high or low) shown as in Supplementary Figure 
S1. 
  
  
Supplementary Figure 3. Growth inhibitory effects of gefitinib and erbitux in 
glioma cells in vitro. Metabolic activity reflecting number of viable cells was assessed 
by MTT assay at 72 h of exposure to gefitinib or erbitux. Data are presented as mean 
± SEM normalized to untreated cells in triplicate or sixtuplicate (n=2) (*p<0.05, 
**p<0.01, effect of gefitinib compared to control, #p<0.05, # #p<0.01, effect of erbitux 
compared to control, one-way ANOVA with Bonferroni correction). 
 
  
Supplementary Table 1. Source of glioma-initiating cell 
(GIC) models: patient and tumor characteristics. 
 Age Gender Histological diagnosis 
T-325 49 Male Recurrent glioblastoma 
T-269 68 Male Glioblastoma 
S-24 44 Female Recurrent glioblastoma 
ZH-161 57 Male Recurrent glioblastoma 
ZH-305 78 Female Recurrent glioblastoma 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 2. Correlation analyses for ERBB family members in glioma cell lines.* 
Basal levels 
(GIC+LTC) 
receptors 
 
ERBB1 protein 
pEGFR 
(ERBB1) 
protein 
 
ERBB2 mRNA 
 
ERBB2 protein 
 
ERBB3 mRNA 
 
ERBB3 protein 
pERBB3 
protein 
 
ERBB4 mRNA 
 
 
EGFR (ERBB1) 
mRNA 
 
 
r=-0.31, p=0.27 
r=-0.43, p=0.24 
r=0.41, p=0.49 
 
 
r=0.28, p=0.33 
r=0.70, p=0.03 
r=0.08, p=0.90 
 
 
r=0.43, p=0.12 
r=0.67, p=0.05 
r=0.15, p=0.81 
 
 
r=-0.28, p=0.32 
r=-0.4, p=0.28 
r=0.39, p=0.50 
 
 
r=-0.23, p=0.42 
r=-0.24, p=0.53 
r=0.88, p=0.05 
 
 
r=-0.23, p=0.42 
r=-0.32, p=0.41 
r=0.75, p=0.15 
 
 
r=-0.37, p=0.19 
r=-0.61, p=0.1 
r=0.91, p=0.03 
 
 
r=0.09, p=0.77 
r=0.67, p=0.07 
r=-0.41, p=0.49 
 
 
EGFR (ERBB1) 
protein 
  
 
r=-0.22, p=0.45 
r=-0.50, p=0.17 
r=-0.29, p=0.63 
 
 
r=-0.16, p=0.58 
r=-0.17, p=0.65 
r=-0.30, p=0.61 
 
 
r=-0.09, p=0.77 
r=0.10, p=0.79 
r=0.39, p=0.51 
 
 
r=-0.003, p=0.99 
r=0.004, p=0.99 
r=-0.88, p=0.05 
 
 
r=0.01, p=0.98 
r=0.01, p=0.97 
r=-0.63, p=0.25 
 
 
r=-0.17, p=0.55 
r=-0.15, p=0.68 
r=-0.95, p=0.01 
 
 
r=0.43, p=0.14 
r=0.26, p=0.54 
r=0.52, p=0.37 
 
pEGFR 
(ERBB1) 
protein 
    
r=-0.06, p=0.83 
r=0.73, p=0.02 
r=-0.38, p=0.52 
 
 
r=-0.41, p=0.14 
r=-0.15, p=0.70 
r=-0.35, p=0.55 
 
 
r=-0.21, p=0.47 
r=--0.07 p=0.87 
r=0.38, p=0.53 
 
 
r=-0.23, p=0.43 
r=-0.08, p=0.83 
r=0.38, p=0.53 
 
 
r=-0.51, p=0.06 
r=-0.37, p=0.32 
r=0.20, p=0.75 
 
 
r=-0.16, p=0.61 
r=0.32, p=0.43 
r=-0.88, p=0.05 
ERBB2 mRNA 
    
 
r=0.57, p=0.03 
r=0.49, p=0.17 
r=0.64, p=0.24 
 
 
r=0.51, p=0.06 
r=0.49, p=0.18 
r=0.5, p=0.38 
 
 
r=0.51, p=0.06 
r=0.48, p=0.19 
r=0.63, p=0.26 
 
 
r=0.15, p=0.6 
r=-0.02, p=0.95 
r=0.51, p=0.38 
 
 
r=0.06, p=0.85 
r=0.40, p=0.32 
r=0.43, p=0.47 
 
 
ERBB2 
protein 
      
r=0.9, p=0.0001 
r=0.91, p=0.0006 
r=-0.2, p=0.74 
 
 
r=0.9, p=0.0001 
r=0.91, p=0.0006 
r=-0.15, p=0.81 
 
 
r=0.67, p=0.008 
r=0.62, p=0.08 
r=-0.12, p=0.84 
 
 
r=-0.15, p=0.60 
r=-0.14, p=0.74 
r=0.5, p=0.39 
 
 
ERBB3 
mRNA 
     
 
 
r=0.99, p=0.0001 
r=0.99, p=0.0001 
r=-0.68, p=0.21 
 
 
r=0.56, p=0.03 
r=0.54, p=0.13 
r=0.87, p=0.05 
 
 
r=-0.08, p=0.78 
r=-0.02, p=0.94 
r=-0.38, p=0.52 
 
 
ERBB3 
protein 
       
 
r=0.58, p=0.03 
r=0.56, p=0.12 
r=0.62, p=0.26 
 
 
r=-0.08, p=0.78 
r=-0.02, p=0.96 
r=0.3, p=0.63 
 
 
pERBB3 
protein 
        
 
r=-0.28, p=0.35 
r=-0.33, p=0.41 
r=-0.42, p=0.50 
 
*LTC and GIC pooled (upper lane), or LTC alone (middle lane) or GIC alone (lower lane). 
 
  
Supplementary Table 3. Correlation analyses for EGF 
ligand family members in glioma cell lines.* 
Basal levels 
(GIC+LTC) 
ligands 
 
 
NRG1 mRNA 
 
 
TGF-ɑ mRNA 
 
 
EREG mRNA 
 
 
BTC mRNA 
 
EGF mRNA 
 
r=0.68, p=0.01 
r=0.69, p=0.04 
    r=0.87, p=0.12 
 
r=-0.18, p=0.54   
r=-0.25, p=0.51 
r=0.23, p=0.7 
 
r=0.16, p=0.57      
r=-0.03, p=0.92 
r=0.49, p=0.4 
 
r=0.04, p=0.88    
r=-0.43, p=0.25 
r=0.46, p=0.43 
NRG1 mRNA 
   
r=0.02, p=0.94 
r=-0.06, p=0.86 
r=0.93, p=0.07 
 
 
r=-0.15, p=0.60 
r=-0.19, p=0.62 
r=0.99, p=0.008 
 
 
r=-0.3, p=0.31 
r=-0.62, p=0.05 
r=0.9, p=0.001 
TGF-ɑ mRNA 
    
r=-0.02, p=0.94 
r=-0.17, p=0.64 
r=0.85, p=0.07 
 
 
r=0.03, p=0.91 
r=-0.03, p=0.92 
r=0.91, p=0.03 
EREG mRNA 
     
r=0.91, p=0.0001 
r=0.33, p=0.39 
r=0.99, p=0.002 
 
*LTC and GIC pooled (upper lane), or LTC alone (middle 
lane) or GIC alone (lower lane). 
 
  
Supplementary Table 4. Correlation analyses for EGF receptor and ligand family members in 
glioma cell lines.* 
Basal levels 
(GIC+LTC) 
ligands 
 
 
ERBB1 mRNA 
 
 
ERBB1 protein 
 
pEGFR 
(ERBB1) 
protein 
 
 
ERBB2 mRNA 
 
 
ERBB2 protein 
 
 
ERBB3 mRNA 
 
 
ERBB3 protein 
 
pERBB3 
protein 
 
 
ERBB4 mRNA 
 
EGF mRNA 
 
r=0.57, p=0.03 
r=0.64, p=0.06 
r=0.39, p=0.52 
 
r=-0.01,p=0.96 
r=0.12, p=0.78 
r=-0.35, p=0.58 
 
r=0.1, p=0.76 
r=0.46, p=0.22 
r=0.42, p=0.47 
 
r=0.39, p=0.15 
r=0.36, p=0.33 
r=0.61, p=0.28 
 
r=-0.16, p=0.58 
r=-0.28, p=0.46 
r=0.3, p=0.63 
 
r=-0.17, p=0.56 
r=-0.24, p=0.53 
r=0.73, p=0.16 
 
r=-0.18, p=0.53 
r=-0.25, p=0.51 
r=0.31, p=0.61 
 
r=-0.36, p=0.19 
r=-0.57, p=0.10 
r=0.43, p=0.46 
 
r=0.1, p=0.74 
r=0.7, p=0.05 
r=-0.14, p=0.82 
 
 
NRG1 mRNA 
 
 
r=0.57, p=0.04 
r=0.58, p=0.1 
r=-0.86, p=0.14 
 
 
r=-0.43, p=0.14 
r=-0.41,p=0.27 
r=0.47, p=0.53 
 
 
r=-0.1, p=0.74 
r=0.76, p=0.02 
r=0.21, p=0.79 
 
 
r=0.75, p=0.003 
r=0.7, p=0.04 
r=0.64, p=0.36 
 
 
r=0.19, p=0.53 
r=0.006, p=0.98 
r=0.85, p=0.15 
 
 
r=0.08, p=0.79 
r=-0.02, p=0.95 
r=0.76, p=0.24 
 
 
r=0.07, p=0.80 
r=-0.03 p=0.93 
r=-0.36, p=0.63 
 
 
r=0.13, p=0.66 
r=-0.09, p=0.81 
r=0.11, p=0.89 
 
 
r=-0.07, p=0.82 
r=0.46, p=0.24 
r=0.06, p=0.94 
 
 
TGF-ɑ mRNA 
 
 
r=-0.26, p=0.38 
r=-0.2, p=0.49 
r=-0.68, p=0.2 
 
 
r=0.05, p=0.85 
r=0.02, p=0.97 
r=0.71, p=0.17 
 
 
r=-0.19,p=0.51 
r=-0.07, p=0.86 
r=-0.22,p=0.72 
 
 
r=0.49, p=0.07 
r=0.48, p=0.19 
r=0.33, p=0.59 
 
 
r=0.86, p=0.0001 
r=0.88, p=0.001 
r=0.89, p=0.04 
 
 
r=0.98, p=0.0001 
r=0.99, p=0.0001 
r=-0.44, p=0.46 
 
 
r=0.98, p=0.0001 
r=-0.99,p=0.0001 
r=-0.4, p=0.48 
 
 
r=0.49, p=0.07 
r=0.48, p=0.19 
r=-0.5, p=0.38 
 
 
r=-0.02, p=0.96 
r=0.02, p=0.96 
r=0.51, p=0.39 
 
 
EREG mRNA 
 
 
r=-0.3, p=0.29 
r=-0.3, p=0.47 
r=-0.47, p=0.42 
 
 
r=0.08, p=0.78 
r=-0.43, p=0.25 
r=0.37, p=0.54 
 
 
r=0.24, p=0.40 
r=-0.28, p=0.45 
r=0.22, p=0.72 
 
 
r=-0.2, p=0.47 
r=-0.58, p=0.1 
r=0.34, p=0.58 
 
 
r=-0.19, p=0.51 
r=-0.32, p=0.3 
r=0.82, p=0.09 
 
 
r=-0.11, p=0.69 
r=-0.18, p=0.63 
r=-0.12, p=0.85 
 
 
r=-0.12, p=0.68 
r=-0.18, p=0.63 
r=-0.48, p=0.41 
 
 
r=-0.12, p=0.68 
r=0.027, p=0.94 
r=-0.15, p=0.8 
 
 
r=0.08, p=0.78 
r=-0.17, p=0.68 
r=0.02, p=0.97 
 
 
BTC mRNA 
 
 
r=-0.42, p=0.13 
r=-0.54, p=0.13 
r=-0.54, p=0.35 
 
 
r=0.24, p=0.42 
r=-0.03, p=0.94 
r=-0.48, p=0.42 
 
 
r=0.15,p=0.61 
r=-0.5, p=0.39 
r=0.14, p=0.82 
 
 
r=-0.20, p=0.48 
r=-0.57, p=0.1 
r=0.33, p=0.58 
 
 
r=-0.09., p=0.76 
r=-0.07, p=0.85 
r=0.84, p=0.07 
 
 
r=-0.08, p=0.77 
r=-0.09, p=0.80 
r=-0.18, p=0.76 
 
 
r=-0.08., p=0.87 
r=-0.09, p=0.81 
r=-0.48, p=0.41 
 
 
r=-0.17, p=0.55 
r=-0.17, p=0.65 
r=-0.26, p=0.66 
 
 
r=0.12, p=0.68 
r=-0.56, p=0.15 
r=0.14, p=0.82 
 
*LTC and GIC pooled (upper lane), or LTC alone (middle lane) or GIC alone (lower lane). 
 
 
